How to Help Your Patients Find Amoxapine in Stock: A Provider's Guide

Your Patients Can't Find Their Amoxapine — Here's How You Can Help

When patients call your office saying they can't fill their Amoxapine prescription, it's more than an inconvenience — it's a clinical concern. Abrupt discontinuation of a tricyclic antidepressant can trigger withdrawal symptoms and depressive relapse. As a prescriber, you're in a unique position to help patients navigate the current shortage and maintain treatment continuity.

This guide provides a practical, step-by-step framework for helping your patients access Amoxapine — or transition safely to an alternative when the medication cannot be found.

Current Availability

Amoxapine (formerly branded as Asendin) has been in an active drug shortage since August 2024. Key facts for your practice:

• Sole manufacturer: Teva Pharmaceuticals is the only US producer of generic Amoxapine tablets
• Available strengths: 25 mg, 50 mg, 100 mg, and 150 mg tablets (intermittent availability varies by strength)
• Brand product: Asendin is discontinued in the US — not available
• Shortage status: Listed by ASHP (created August 2024, updated April 2025) and tracked by the FDA

For the full shortage timeline and background, see our provider briefing on the Amoxapine shortage for prescribers.

Why Patients Can't Find Amoxapine

Understanding the barriers your patients face helps you intervene more effectively:

Single-Source Supply

With only Teva producing Amoxapine, there is no fallback supplier. Any production issue — from raw material delays to quality holds — creates immediate nationwide impact.

Pharmacy Stocking Patterns

Most chain pharmacies stock based on demand. Because Amoxapine is a low-volume medication, many pharmacies don't carry it routinely. During a shortage, even pharmacies that normally stock it may be unable to reorder.

Wholesaler Allocation

During shortages, wholesalers often allocate limited supply based on each pharmacy's purchasing history. Pharmacies that rarely order Amoxapine may receive little to no allocation, even if they have patients waiting.

Patient Awareness Gaps

Many patients don't know about alternative pharmacy options (independent pharmacies, mail-order, compounding). They may call two or three chain pharmacies, get turned away, and then feel stuck.

What Providers Can Do: 5 Practical Steps

Step 1: Identify Your Amoxapine Patients Proactively

Run a report in your EHR or practice management system to identify all patients currently prescribed Amoxapine. Rather than waiting for patients to call with fill problems, reach out proactively to:

• Confirm they've been able to fill their prescriptions
• Discuss contingency plans before a crisis
• Document alternative treatment preferences in their chart

Step 2: Direct Patients to Medfinder

Medfinder for Providers is a free tool that searches pharmacy availability in real time. You can:

• Search for pharmacies with Amoxapine in stock near your patient's location
• Provide patients with specific pharmacy names and phone numbers
• Reduce the burden on your front office staff by giving patients a self-service tool

Include medfinder.com/providers in patient-facing handouts or after-visit summaries.

Step 3: Prescribe Flexibly

Maximize your patients' chances of filling their prescriptions by being flexible with your prescribing:

• Consider alternative strengths. If 50 mg is unavailable, prescribe 25 mg (quantity doubled) or adjust to 100 mg if clinically appropriate
• Allow pharmacist substitution. Note on the prescription that alternative strengths are acceptable if the prescribed strength is unavailable
• Send prescriptions to multiple pharmacies. If your state allows it, consider sending the prescription to an independent pharmacy as a backup

Step 4: Have a Transition Plan Ready

For each Amoxapine patient, document a preferred alternative in the chart. This allows for a faster transition if the medication becomes completely unavailable. Recommended alternatives include:

• Nortriptyline (Pamelor): 25–150 mg/day. Secondary amine TCA, good tolerability, widely available. No dopamine-blocking activity.
• Desipramine (Norpramin): 100–200 mg/day. Most norepinephrine-selective TCA, lowest anticholinergic burden. Therapeutic drug monitoring available.
• Doxepin: 75–150 mg/day. Strong antihistamine/sedating properties; good for depression with insomnia.
• Imipramine (Tofranil): 75–200 mg/day. Dual NE/5-HT reuptake inhibition. Extensive evidence base.

Note: Amoxapine has unique D2/D4 receptor antagonism. For patients with psychotic depression, pairing a TCA with a low-dose atypical antipsychotic may be necessary to replicate this effect.

For patient-friendly alternative information, direct patients to our guide on alternatives to Amoxapine.

Step 5: Consider Compounding

If commercial Amoxapine tablets are unavailable and the patient needs to stay on the medication, compounding is a viable option:

• Compounding pharmacies can prepare Amoxapine capsules from USP-grade raw material
• Write the prescription specifying compounded Amoxapine with the desired strength
• Verify that the compounding pharmacy uses FDA-registered ingredient sources
• Insurance may not cover compounded medications — discuss cost with the patient (typically $30–$60 per month)

Alternative Medications: Quick Reference

Here is a comparison table of common TCA alternatives to Amoxapine:

• Nortriptyline: 25–150 mg/day | Better tolerability | No D2 blockade | $10–$30/month
• Desipramine: 100–200 mg/day | Least anticholinergic | No D2 blockade | $15–$45/month
• Doxepin: 75–150 mg/day | Strong sedation | Good for insomnia | $10–$25/month
• Imipramine: 75–200 mg/day | Dual NE/5-HT | Extensive evidence | $10–$30/month

Workflow Tips for Your Practice

Incorporate these into your clinical workflow to stay ahead of the shortage:

• Add Amoxapine to your shortage watch list. Check ASHP and FDA shortage databases monthly.
• Flag Amoxapine patients in your EHR. Use a tag or problem list entry so any provider in your practice can quickly identify these patients.
• Create a standard handout. Prepare a one-page resource for patients that includes Medfinder (medfinder.com/providers), tips for finding the medication, and contact information for your office if they need help.
• Brief your front office staff. Make sure staff who take patient calls know the basic steps: check Medfinder, try independent pharmacies, and schedule a visit or telehealth appointment if the patient can't fill their prescription.
• Document everything. Record shortage-related communication, alternative discussions, and patient preferences in the medical record.

Final Thoughts

The Amoxapine shortage requires provider engagement beyond the prescription pad. By proactively identifying affected patients, leveraging tools like Medfinder for Providers, prescribing flexibly, and maintaining documented transition plans, you can protect your patients from treatment interruptions.

The shortage may continue throughout 2026. Building these practices into your workflow now will save time and improve outcomes for your Amoxapine patients.

For related provider resources, see our briefing on the Amoxapine shortage for prescribers and our guide on how to help patients save money on Amoxapine.